not tagged
bms
today's industry symposium featured a presentation by dr. suzanne trudel that identified fcrh5 and gprcsd as highly promising novel targets in myeloma, demonstrating deep responses in heavily pre-treated patients including those who are triple refractory. #ims2022 
To cure myeloma by fostering research, education and excellence in clinical care worldwide.